SCHEMBL4958024

SCHEMBL4958024

CCCCc1nc2ncccc2c(=O)n1-c1ccc(N)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.57
PDE4B Q07343 2/20 0.57
PDE4C Q08493 2/20 0.57
PDE4D Q08499 2/20 0.57
LMNA P02545 3/20 0.56
MAPK1 P28482 1/20 0.56
PDE10A Q9Y233 2/20 0.52
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP2D6 P10635 1/20 0.44
KAT2B Q92831 1/20 0.44
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957996 0.84 LMNA (0.46) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL4958923 0.83 LMNA (0.80) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL4958469 0.80 LMNA (0.74) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL14115051 0.78 LMNA (0.48) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL14115102 0.78 LMNA (0.58) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL4957091 0.76 LMNA (0.53) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL1484471 0.75 SMN1; SMN2 (0.54) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL12857748 0.75 IDO1 (0.51) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL4959512 0.75 MEN1 (0.73) LMNAMAPK1PDE10AALDH1A1CYP1A2
SCHEMBL4959299 0.75 LMNA (0.63) PDE4APDE4BPDE4CPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008094909-A2 QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-07 WO disclosed
WO-2008094909-A2 QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-07 WO disclosed